Rate Video

ASH 2022 | Addressing cardiotoxicity concerns with the use of gilteritinib

Eunice Wang • 12 Dec 2022

ASH 2022

Acute Myeloid Leukemia Leukemia Dasatinib Gilteritinib Imatinib Nilotinib

Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, comments on the importance of managing the potential cardiotoxicity associated with the use of gilteritinib when treating patients with acute myeloid leukemia (AML). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

The potential of menin inhibitors in specific molecular subsets of AML & ALL

Eunice Wang • 29 Sep 2022

KOMET-001: targeting menin-KMT2A in AML

Eunice Wang • 27 May 2021

FLT3 mutation clearance rate in patients with newly diagnosed AML

Eunice Wang • 13 Dec 2021

Strategies to manipulate the immune system in myeloid malignancies

Eunice Wang • 29 Sep 2022

Related Videos

Key challenges of using the intestinal microbiome as a biomarker

CAR T-cell therapy: the importance of LTFU

The future of AML therapy

Andreas Burchert

Treating pediatric patients with hematological malignancies

Claudia Rössig